Commissioner Dalli's message on the occasion of the 6th European Patients' Rights day

18.04.2012

 

Today, 18th April marks the 6th European Patients’ Rights Day.  The European healthcare biotechnology industry is at the heart of advancing citizens’ rights of access to the most modern and innovative medicines available.  Already more than 350 million patients have benefited from approved medicines manufactured through biotechnology to treat and prevent a multitude of illnesses such as stroke, cancer, diabetes, multiple sclerosis and rare diseases.  It is estimated that by 2014 50% of the top 100 drugs will be biotech medicines.

 

European Policy makers need to ensure therefore a supportive regulatory framework for the healthcare biotechnology sector to flourish and continue to provide patients throughout Europe with the choice of the best medicine available to meet their needs. We must ensure that patients have access to safe, effective and high quality medicines.

 

Of particular importance to achieving this is the revision of the Clinical Trials Directive- it is essential that discussions move forward at a faster rate to achieve asimplified and coherent clinical trials framework in Europe for the benefit of patients.

 

Cost containment measures taking place in many Member States across the EU should not be at the expense of the health and well-being of its citizens and we encourage governments to continue to provide support and financing for innovation in medicine.

 

Watch Commissioner Dalli’s speech on European Patients Rights Day here